Journal
JOURNAL OF IMMUNOLOGY
Volume 185, Issue 7, Pages 4095-4100Publisher
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1000986
Keywords
-
Categories
Funding
- National Institutes of Health
- National Multiple Sclerosis Society
- Commonwealth of Pennsylvania Department of Health
Ask authors/readers for more resources
Multiple sclerosis is a CD4(+) T cell-mediated autoimmune disease affecting the CNS. Multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis (EAE), have been thought to be Th1-mediated diseases. However, recent studies provide strong evidence that the major pathogenic T cell subsets in EAE are Th17 cells. IL-9, a hematopoietic growth factor, is considered to be a mediator of Th17 cells, but the precise mechanisms of its action are largely unknown. The present study was designed to investigate the role of IL-9 in autoimmune demyelination. IL-9 blockade with anti-IL-9 mAb inhibited the development of EAE, reduced the serum levels of IL-17, the CNS mRNA expression of IL-17, IL-6, IFN-gamma, and TNF-alpha, and the myelin oligodendrocyte glycoprotein (MOG)-induced IL-17, IFN-g secretion of lymphocytes. Furthermore, anti-IL-9 mAb in culture suppressed IL-17 production of MOG-reactive T cells and their potency in adoptive transfer EAE. These findings indicate that the protective effect of IL-9 blockade in EAE was likely mediated via inhibition of the development of MOG peptide-specific T cells, which in turn led to reduced infiltration of T cells into the CNS. Thus, anti-IL-9 mAb treatment may provide an effective therapeutic strategy against autoimmune diseases. The Journal of Immunology, 2010, 185: 4095-4100.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available